clinical trial · NCT00648427
Fasting Study of Paroxetine Hydrochloride Controlled-Release Tablets 25 mg to Paxil CR™ Tablets 25 mg
HealthyParoxetine Hydrochloride Controlled-Release Tablets 25 mgPaxil CR™ Tablets 25 mg
brief summary
The objective of this study was to investigate the bioequivalence of Mylan's paroxetine hydrochloride controlled-release 25 mg tablets to GSK's Paxil CR™ 25 mg tablets following a single, oral 25 mg (1 x 25 mg) dose administered under fasting conditions.
started
Apr 1, 2005
primary completion
Apr 1, 2005
completion
May 1, 2005
last updated
Apr 24, 2024
official title
Single-Dose Fasting In Vivo Bioequivalence Study of Paroxetine Hydrochloride Controlled-Release Tablets (25 mg; Mylan) to Paxil CR™ Tablets (25 mg; GlaxoSmithKline) in Healthy Volunteers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol